Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) continues to be a major cause of cancer deaths. Previous investigation has suggested that metformin use can contribute to improved outcomes in NSCLC patients. However, this association is not uniform in all analyzed cohorts, implying that patient characteristics might lead to disparate results. Identification of patient characteristics that affect the association of metformin use with clinical benefit might clarify the drug's effect on lung cancer outcomes and lead to more rational design of clinical trials of metformin's utility as an intervention. In this study, we examined the association of metformin use with long-term mortality benefit in patients with NSCLC and the possible modulation of this benefit by body mass index (BMI) and s

SUBMITTER: Elkin PL 

PROVIDER: S-EPMC9463413 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature